Gene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
Uniqures new COO to oversee GMP
AppointmentsGene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
Vernalis receives next veto by FDA
Latest NewsBritish biotech company Vernalis has to deal with another Complete Response Letter by US authority FDA – this time regarding the New Drug Application for its cough and cold treatment CCP-08.
Hansas immunomodulatory enzyme does the job
Latest NewsSweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
Biosimilars labelling
OpinionEuropaBio has developed recommendations for changes to the Summary of Product Characteristics (SmPC) of biosimilars that would result in an enhanced level of transparency for the label.
TC Biopharm gets €4m Horizon2020 grant
Latest NewsThe Scottish biotech company TC Biopharm (TCB) has been awarded a €4m grant from the European Unions Horizon 2020 programme.
Benefits and challenges in pharma innovation
OpinionWe are living in a world of cutting-edge science, which holds the potential to transform the landscape for patients living with common and rare diseases within the next five years. This is of particular importance as we face a demographic evolution that will see an already-aging population expand significantly and rapidly across the globe.
Zealand taps US market
Latest NewsDanish diabetes biotech Zealand Pharma has started its initial public offering in the US at Nasdaq Global Select Market. It plans to raise US$75m to fund clinical trails.
Autolus: Accelerating T-cell products
AppointmentsIn preparation for the development and commercialisation of Autolus T-cell products, the London based company announced four new senior leadership appointments.
Adocia: Advancing diabetes portfolio
AppointmentsFollowing Novo Nordisk, Dr. Stanislav Glezer has joined the French biopharmaceutical company Adocia as the new Chief Medical Officer. He will be responsible for designing and executing the clinical development plan of its diabetes treatments.
Uniqure from now on alone
Latest NewsItalian pharma company Chiesi Farmaceutici withdraws from a co-development agreement with gene therapy pioneer Uniqure. This will add US$1.5m to Uniqures expenses this year.